PURPOSE OF INVESTIGATION: To define the deletion or over-expression of p53 genes and their prognostic significance in epithelial ovarian cancers. METHODS: A total of 26 patients with epithelial ovarian cancer, who had undergone second-look laparotomy after primary surgery and six courses of platinum-based chemotherapy were included in the study. Paraffin-embedded archival tissue samples of all cases were examined for deletion and over-expression of p53 gene by FISH and immunohistochemical methods, respectively. The relation between these findings and clinico-pathological prognosticators or survival of the patients were analyzed by the Fisher Exact chi2 test, Cox regression model and life table analysis. RESULTS: p53 gene deletion, related to single or double allele, was determined in all cases with a range of 6% to 75% of the cancer cells. When 40% was accepted as the cut-off ratio for the deletion rate, seven (26.9%) of the cases were observed to have p53 deletion. Although p53 over-expression was defined in 12 (46.1%) patients, four of whom were also accompanied by p53 deletion, there was no relation between the p53 deletion and over-expression (p>0.05). p53 deletion was also not related to any prognostic factors or survival of the patients (p>0.05). However, cases with p53 over-expression had significantly more advanced stage and higher-grade tumors, and shorter median survival (p>0.05-0.01). CONCLUSION: p53 gene mutation determined by over-expression of p53 protein has been suggested as an important prognostic factor for epithelial ovarian cancer, however, it has not always been accompanied by p53 deletion.
PURPOSE OF INVESTIGATION: To define the deletion or over-expression of p53 genes and their prognostic significance in epithelial ovarian cancers. METHODS: A total of 26 patients with epithelial ovarian cancer, who had undergone second-look laparotomy after primary surgery and six courses of platinum-based chemotherapy were included in the study. Paraffin-embedded archival tissue samples of all cases were examined for deletion and over-expression of p53 gene by FISH and immunohistochemical methods, respectively. The relation between these findings and clinico-pathological prognosticators or survival of the patients were analyzed by the Fisher Exact chi2 test, Cox regression model and life table analysis. RESULTS:p53 gene deletion, related to single or double allele, was determined in all cases with a range of 6% to 75% of the cancer cells. When 40% was accepted as the cut-off ratio for the deletion rate, seven (26.9%) of the cases were observed to have p53 deletion. Although p53 over-expression was defined in 12 (46.1%) patients, four of whom were also accompanied by p53 deletion, there was no relation between the p53 deletion and over-expression (p>0.05). p53 deletion was also not related to any prognostic factors or survival of the patients (p>0.05). However, cases with p53 over-expression had significantly more advanced stage and higher-grade tumors, and shorter median survival (p>0.05-0.01). CONCLUSION:p53 gene mutation determined by over-expression of p53 protein has been suggested as an important prognostic factor for epithelial ovarian cancer, however, it has not always been accompanied by p53 deletion.
Authors: Kathleen M Darcy; William E Brady; John W McBroom; Jeffrey G Bell; Robert C Young; William P McGuire; R Ilona Linnoila; Denver Hendricks; Tomas Bonome; John H Farley Journal: Gynecol Oncol Date: 2008-10-02 Impact factor: 5.482
Authors: P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock Journal: Br J Cancer Date: 2009-06-09 Impact factor: 7.640